Stock Market News 11 November 2025

Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones set a new record on Nov. 11, 2025, while the Nasdaq slipped as Nvidia fell after SoftBank disclosed a $5.8B stake sale. Europe rallied on rising BoE rate‑cut bets and Vodafone’s first dividend hike in years. Here’s

11 November 2025

Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

Cisco (CSCO) Stock Today — November 11, 2025: Options Surge, Partner-Program Updates, Earnings Tomorrow

Summary (Nov. 11, 2025) Cisco stock today: price, range and volume As of 4:30 p.m. ET (21:30 UTC), CSCO last traded near $71.71, down about 0.47% on the day. The stock opened at $71.74 and moved between $71.10 and $72.24

11 November 2025

Cisco · Earnings · Options Trading · Stock Market · Technology News

NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Nvidia (NVDA) Stock Today: SoftBank Exits $5.8B Stake, CoreWeave Cuts Outlook; NVDA Slips Ahead of Nov. 19 Earnings — November 11, 2025

Updated: November 11, 2025 — U.S. market close Key Takeaways NVDA Price Action Today (11/11/2025) Nvidia closed at $194.38, down $4.67 (-2.35%) from Monday’s close of $199.05. Intraday range: $191.30–$195.42 on ~125.25M shares traded. Prior close: $199.05; 52‑week range: $86.62–$212.19.

11 November 2025

Earnings Reports · Investment Analysis · NASDAQ:NVDA · NVIDIA · Stock Market · Technology News

Tesla’s Stock Skyrockets on AI Hype – Latest Price Jump, Earnings Shocks & Bold 2025 Forecasts

Tesla Stock Today (11/11/2025): TSLA Slips as China Sales Hit 3‑Year Low, Musk’s Form 4 Lands, and $60/Day Rentals Go Live

Updated November 11, 2025 Key Takeaways TSLA Price Action: What’s Moving the Tape Tesla shares edged lower on Tuesday, November 11, 2025, hovering near $439.6 in afternoon trading. The stock’s day range sat at $432.36–$442.49, within a 52‑week band of

11 November 2025

China Business · Electric Vehicles · Financial Reports · NASDAQ:TSLA · Stock Market · Tesla News

Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft (MSFT) Stock Today — Nov. 11, 2025: Shares Edge Higher as $10B Portugal AI Hub, Patch Tuesday Fixes and New Enterprise AI Deals Dominate Headlines

Updated Nov. 11, 2025 Key takeaways Market snapshot: MSFT price action Microsoft stock traded modestly higher on Tuesday, recently around $508.68, up $2.91 (~0.6%) versus the prior close. The session’s high/low printed near $509.54/$502.44, with intraday volume just under 17

11 November 2025

Artificial Intelligence · Enterprise Technology · Financial Updates · Microsoft News · NASDAQ:MSFT · Stock Market

Apple’s July 2025 Bombshells: Foldable iPhone, AI Secrets, Encryption Showdown & More

Apple Stock Today (AAPL) — 11/11/2025: Shares Climb as AI-Spending Discipline Wins Fans; Dividend Arrives This Week

Summary: Apple stock pushed higher on Tuesday, November 11, 2025, trading around $275 and up roughly 2% on the day. The move keeps AAPL within sight of its 52‑week high as investors reward Apple’s comparatively restrained AI spending and weigh

11 November 2025

Apple Inc · Artificial Intelligence · Dividends · Investing · Stock Market

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Published: November 11, 2025 Moderna, Inc. (NASDAQ: MRNA) drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic

11 November 2025

Company Updates · Financial Analysis · Investment News · NASDAQ:MRNA · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs

11 November 2025

Business News · Mergers & Acquisitions · NYSE:MRK · NYSE:NVO · NYSE:PFE · Oncology · Pharmaceuticals · Stock Market

Leifras (NASDAQ: LFS) Rockets on November 11, 2025: Top Gainer Status, Quiet‑Period Countdown, and What’s Driving the Surge

Leifras (LFS) ripped higher on Nov. 11, 2025, topping U.S. gainers as its IPO quiet period nears an end. Here’s what changed today—and what to watch next. Key takeaways What happened today (Tuesday, November 11, 2025) Shares of Leifras Co.,

11 November 2025

Financial Analysis · Investment Strategies · Market Movers · Nasdaq News · Stock Market

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and

11 November 2025

Cancer Research · FDA Approvals · Immunotherapy · NYSE:MRK · Pharma News · Stock Market

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month

11 November 2025

Collaborations · Company News · Health Industry · Pharmaceuticals · Stock Market

Vor Biopharma (VOR) Prices $100M Stock Offering at $10; Shares Slide as Investors Weigh Dilution — Nov. 11, 2025

What happened today Vor Biopharma Inc. (NASDAQ: VOR) priced an underwritten public offering of 10 million common shares at $10.00 per share for $100 million in expected gross proceeds. The company granted underwriters a 30‑day option to purchase up to

11 November 2025

Biotech · Financial News · Investments · NASDAQ:VOR · Public Offerings · Stock Market